Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — H1 2023 Earnings Presentation
14 slides from Imricor Medical Systems's earnings presentation, Aug 24, 2023
Slide 1: H1 FY23 Investor Presentation
For personal use only H1 FY23 Investor Presentation August 2023 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to place undue reliance on
Slide 3: Key achievements in H1
For personal use only Key achievements in H1
Slide 4: H1 Highlights
H1 Highlights • Received an approved Investigational Device Exemption (IDE) from the US FDA to commence global clinical trial aimed at supporting FDA approval For personal use only • GE HealthCare and Imricor signed an MSA to make Imricor products work with GE HealthCare MRI systems • GE HealthCare
Slide 5: AI Product Update
AI Product Update NorthStar1 development continues with AI augmentations For personal use only • First version of NorthStar is frozen and is progressing toward regulatory approvals • AI augmentations are planned for future revisions to realise full value of 3D MRI imaging for ablations and other int
Slide 6: Financial Performance
For personal use only Financial Performance
Slide 7: Profit and loss
Profit and loss US$’000 HY23 HY22 Commentary Revenue 199 538 • Costs and non-R&D expenses decreased 7% primarily due For personal use only to lower staffing costs ($224) and inventory reserves ($344), Costs and non-R&D expenses (5,194) (5,588) which were partially offset by increases in professional
Slide 8: Balance sheet
Balance sheet US$’000 23-Jun Dec-22 Cash and cash equivalents 1,509 5,688 Accounts receivable 124 126 Commentary For personal use only Inventory 2,228 2,277 Other current assets 658 1,593 • Cash decreased due to continued investments in Research Total current assets 4,519 9,684 & Development coupled
Slide 9: Cashflow
Cashflow US$’000 HY23 HY22 Commentary For personal use only Net loss (9,220) (9,776) • Other non-cash adjustments were down vs. prior Other non-cash adjustments 1,020 1,369 comparative period due to decreases in inventory reserves established in the period and stock-related compensation Change in ot
Slide 10: Business Update and Outlook
For personal use only Business Update and Outlook
Slide 11: Rapid Start to H2
Rapid Start to H2 For personal use only • Executed distribution agreement with AI Faisaliah Medical Systems (FMS), giving FMS exclusive right to market and sell Imricor’s products in the Kingdom of Saudi Arabia (KSA) • Balance sheet bolstered via advantageous A$30 million equity funding facility sec
Slide 12: Key message
Key message Imricor’s mission is to establish a new standard of care for cardiac ablations with real- time iCMR guidance. Cardiac ablation is a US$8bn1 worldwide market For personal use only Primary Drivers of Value Additional Drivers of Value • Expand indications to complex • Grow number of active
Slide 13: Our focus for 2023 remains the same
Our focus for 2023 remains the same For personal use only 1 2 3 Commercialisation VISABL-VT Trial VISABL-AFL Trial • Activating sites (EU) (US) • Increasing procedure • Commence trial • Commence trial volumes across active • Expected to catalyse • First major step into the sites market as value of V
Slide 14: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Vice President, Marketing and
Imricor Medical Systems — H1 2023 Earnings Presentation on 6ix